Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor
receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The
investigators' phase I study has shown that the drug's toxicity is manageable and the maximum
tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib
can improve progression free survival compared with placebo in patients with metastatic
gastric carcinoma who failed two lines of chemotherapy.